OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Mascarenhas on Updates from the MANIFEST Trial in Myelofibrosis

June 11th 2022

John O. Mascarenhas, MD, discusses updates from the phase 2 MANIFEST trial in patients with myelofibrosis.

Dr. Yilmaz on the Benefit of Quizartinib Triplet in AML

June 11th 2022

Musa Yilmaz, MD, discusses composite complete remission and bone marrow transplant rates observed in a phase 1/2 trial in patients with FLT3-ITD–mutated acute myeloid leukemia.

Dr. Eyre on the Design of the BRUIN-MCL-321 Trial in MCL

June 10th 2022

Toby Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD, discusses the design and the rationale of the phase 3 BRUIN-MCL-321 trial in mantle cell lymphoma.

Dr. Cordoba on the Efficacy of Epcoritamab in DLBCL

June 10th 2022

Raul Cordoba, MD, PhD, discusses efficacy data with epcoritamab observed in the phase 1/2 EPCORE NHL-2 trial in relapsed/refractory diffuse large B-cell lymphoma.

Dr. Stein on the SELECT-AML-1 Trial in Newly Diagnosed AML

June 10th 2022

Eytan M. Stein, MD, discusses the phase 2 SELECT-AML-1 trial in patients with newly diagnosed acute myeloid leukemia.

Dr. Stein on the KOMET-001 Trial in Relapsed/Refractory AML

June 10th 2022

Eytan M. Stein, MD, discusses the phase 1/2 KOMET-001 trial in relapsed/refractory acute myeloid leukemia.

Dr. Castillo on the CLOVER-WaM Trial in Waldenström Macroglobulinemia

June 10th 2022

Jorge J. Castillo, MD, discusses the phase 2 CLOVER WaM trial in Waldenström macroglobulinemia.

Dr. Velcheti on the Safety of Nemvaleukin in Solid Tumors

June 7th 2022

Vamsidhar Velcheti, MD, discusses the safety of nemvaleukin alfa in patients with advanced solid tumors in the phase 1/2 ARTISTRY-1 trial.

Dr. Botta on the Evaluation of CT041 in Gastric and Pancreatic Cancer

June 7th 2022

Gregory Botta, MD, PhD, discusses the evaluation of CT041 in patients with advanced gastric and pancreatic cancers in a phase 1b trial.

Dr. Rao on the Rationale of the CASPAR Trial in mCRPC

June 7th 2022

Arpit Rao, MD, discusses the rationale and importance of the phase 3 CASPAR trial in castration-resistant prostate cancer.

Dr. Modi on the Findings of DESTINY-Breast04 in HER2-Low Breast Cancer

June 6th 2022

Shanu Modi, MD, discusses the efficacy findings of the phase 3 DESTINY-Breast04 trial in patients with HER2-low metastatic breast cancer.

Dr. Westin on Subgroup Analysis of ZUMA-7 of Elderly Patients With R/R DLBCL

June 6th 2022

Jason R. Westin, MD, discusses subgroup analysis of elderly patients treated in the ZUMA-7 trial.

Dr. Ansell on the Updated Analysis of ECHELON-1 in Classical Hodgkin Lymphoma

June 5th 2022

Stephen M. Ansell, MD, PhD, discusses the updated analysis of the phase 3 ECHELON-1 in classical Hodgkin lymphoma.

Dr. Shah on the Survival Analysis of Older Patients With B-Cell ALL in the ZUMA-3 Trial

June 5th 2022

Bijal D. Shah, MD, MS, discusses the survival analysis of subgroups of patients with relapsed/refractory B-cell acute lymphoblastic leukemia treated in the phase 3 ZUMA-3 trial.

Dr. Rampal on the Investigation of Navtemadlin in Relapsed/Refractory AML and MPNs

June 4th 2022

Raajit K. Rampal, MD, PhD, discusses the investigation of navtemadlin in relapsed/refractory acute myeloid leukemia and patients with blast phase myeloproliferative neoplasm in a phase 1b/2 trial.

Dr. Falchi on the Use of Epcoritamab with R-CHOP Therapy in High-Risk DLBCL

June 4th 2022

Lorenzo Falchi, MD, discusses the updated findings from the phase 1/2 EPCORE NHL-2 trial trial evaluating the subcutaneous administration of epcoritamab with R-CHOP in patients with high-risk diffuse large B-cell lymphoma.

Dr. Spira on the Potential Role of Adagrasib in NSCLC

June 4th 2022

Alexander I. Spira, MD, PhD, FACP, discusses the adagrasib in patients with non–small cell lung cancer in the phase 2 KRYSTAL-1 trial.

Dr. Wang on the Results of the Phase 3 SHINE Study in MCL

June 3rd 2022

Michael Wang, MD, discusses the results of the phase 3 SHINE trial in older patients with mantle cell lymphoma.

Dr. Ajani on the FDA Approvals of Nivolumab Plus Chemotherapy and Nivolumab Plus Ipilimumab in ESCC

June 2nd 2022

Jaffer A. Ajani, MD, discusses how the FDA approvals of first-line nivolumab plus chemotherapy and nivolumab plus ipilimumab in advanced or metastatic esophageal squamous cell carcinoma will improve treatment in this setting.

Dr. Vaishampayan on the Rationale of the PROBE Trial in RCC

June 1st 2022

Ulka Nitin Vaishampayan, MBBS, discusses the rationale of the phase 3 PROBE trial in advanced renal cell carcinoma.